Sign up for periodic reports and bulletins
FREE access; FREE of commercials; FREE to use
Posted January 12, 2017: by Bill Sardi
During a tumultuous period of turnover of federal agencies just prior to the inauguration of Donald Trump as the 45th President of the United States, the Federal Trade Commission appears to be taking a final shot at a company that in 2009 needled forgetful government officials who didn’t pay their taxes on time.
Posted January 11, 2017: by Bill Sardi
In recent weeks the world has learned the news media creates fake news and/or completely shuns significant news stories to match its own politically correct agendas. So an unequivocal cure for a major brain disease goes unreported. Shame on CNN, CBS, ABC, NBC, the BBC, Reuters, Associated Press and the New York Times.
For a disease considered incurable, a physician in Italy has begun to provide a common B vitamin to successfully treat a debilitating motor-nerve disease commonly known as Parkinson’s disease. The importance of this startling discovery has escaped major news outlets. It should be heralded on television and in newspapers worldwide. But it has only been reported by an obscure European news source. [Ultima Edizione.eu] (Be sure to click the before-and-after video tabs.)
Posted June 6, 2014: by Bill Sardi
You have to utilize the best available evidence today to avert Alzheimer’s disease a couple of decades ahead in your future. That is what the best authorities are saying today. The changes in the brain associated with early Alzheimer’s memory loss begin at least two decades prior to noticeable mental decline. Treatment when symptoms first begin to arise may be too late to reverse deleterious effects upon the brain.
Brain researchers now believe it would be more productive to develop a treatment that will be prescribed in the earliest stages of mental decline. [Molecular Neurodegeneration Oct 2013]
Beta amyloid plaque deposition in the brain may precede Alzheimer’s disease symptoms by 20 years. [Discovery Medicine May 2013]
Posted September 11, 2013: by Bill Sardi
Investigators at Tufts University display striking images of the human brain when it is deficient in vitamin B12. Brain scans show fluid-filled spaces at the center of a shrinking B-12 deficient brain – literally holes in the brain.
A prior study showed that high-dose B vitamins (800 mcg folic acid, 20 mg vitamin B6, 500 micrograms of vitamin B12) slows the rate of shrinkage in the human brain, and more demonstrably reduces (by 7 times) shrinkage of grey matter in the brain.
This study, published in the Journal of the American Geriatrics Society, is more striking because of the photographic images of a shrinking brain accompanied by mental tests which confirms loss of thinking ability as the brain shrinks in size.
Lack of absorption of dietary and supplemental vitamin B12 due to progressive inability to produce stomach acid is cited as a growing concern. Therefore, it may be that widespread H. pylori infection, which is prevalent in more than half of the US population, could be a parallel facto as H. pylori shuts down production of stomach acid.
Another concern is that the most often used anti-diabetic drug, metformin, depletes the body of vitamin B12. Metformin use has been associated with declining mental function. ©2013 Bill Sardi, Knowledge of Health, Inc.
Posted July 8, 2013: by Bill Sardi
This investigator’s report about a vitamin remedy to quell the ongoing epidemic of Alzheimer’s memory loss suggests Big Pharma must have known all along that a vitamin B1 (thiamin) deficiency is associated with or is a cause of abnormalities (brain plaque) observed in both laboratory animals and humans.
A shortage of thiamin had been linked to Down’s Syndrome as far back as 1976. Down’s syndrome subjects develop an early form of Alzheimer’s disease.
That pharmaceutical companies must have known all this but failed to report it is consistent with their narrow profit-making mission to produce synthetic molecules and gain their approval as drugs.
Posted July 7, 2013: by Bill Sardi
The inconceivable is being contemplated – that the intellectual disability among individuals with an inherited developmental disorder (Down’s syndrome) is being partially reversed in animal models of this syndrome with small molecules (example: EGCG from green tea) and may be ready for human application within the next decade, say medical researchers.
Genetic researchers are raising the possibility that certain features of Down’s syndrome, an inherited developmental disorder that affects an estimated 5.8 million people worldwide, can now be reversed or partially corrected by use of small natural molecules. Recent successes in the animal lab provide hope.
Posted November 15, 2012: by Bill Sardi
I was reading a front-page Wall Street Journal report about a medical researcher who believes his company, TauRx Pharmaceuticals Ltd, has a remedy for Alzheimer’s disease. It was a re-run of dated stories about TauRx’s 10-year venture to cure or even slow down the progression of this debilitating brain disease.
God knows how much venture capital TauRX has chewed up in the last 10 years. The company finally completed a small human study. At a 50-milligram dose the tau drug, Rember, produced only modest results in its first small human trial. A 100-mg dose had no positive effect. Full data on these first human studies were not revealed because the TauRx says “it didn’t to protect the company’s commercial interest.” That commercial interest might be that TauRx’s molecule is nothing more than methylene blue, a cheap anti-fungal agent used in fish tanks. While TauRx warns that Rember is different from plain methylene blue, it is a very close molecular cousin that appears to have been altered for the purpose of patent protection rather than improved performance.
Posted September 24, 2012: by Bill Sardi
Comment: without a proven cure for Alzheimer’s disease, clinicians should move vitamin B1 (thiamin) to their “A” list of potential remedies. Coffee, tea, alcohol, sugar, all block B1 absorption. Fat-soluble B1 (benfotiamine) was developed for this very purpose. Accompanying signs of B1 deficiency would be nystagmus (lateral eye twitches), chronic diarrhea, fibromyalgia-like symptoms, heart failure, greying of hair, diabetic complications in eyes and kidneys. — Bill Sardi, Knowledge of Health, Inc.
Posted March 8, 2010: by Bill Sardi
It was November 3, 1906, at a medical meeting in Germany, when Dr. Alois Alzheimer first described a patient named “Augusta” who, at age 51, exhibited abnormal mental, language and behavior problems. Upon her death, the patient’s brain was autopsied and Dr. Alzheimer described a rare and “a peculiar disease of the cerebral cortex.” Accumulation of a form of plaque, now called beta amyloid, characterizes this disease. Today about half of the current 85-plus population exhibits these same tangled, shrunken tissues in their brain that Dr. Alzheimer first observed over 100 years ago.
Epidemiologists, medical scientists who search for the causes of disease in human populations, have been perplexed for decades over the cause of Alzheimer’s disease — the early onset (40s and 50s) of memory-impairment due to abnormal changes in the brain, compared to senile dementia which occurs later in life.
For heretofore unexplained reasons, Alzheimer’s disease is rare, even nonexistent, in some rural undeveloped lands like India and Africa. Alzheimer’s disease appears to be a disease of modern civilization. This suggests an environmental rather than an inherited origin.